<DOC>
	<DOC>NCT02271347</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of Brincidofovir (BCV) when administered as an initial 200mg dose followed by 100mg twice weekly (BIW) for a total of 5 doses.</brief_summary>
	<brief_title>An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease</brief_title>
	<detailed_description />
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Hemorrhagic Fever, Ebola</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<criteria>Positive for Ebola virus RNA in plasma Subject must be able to ingest, absorb, and tolerate oral medication Subject must be willing to use adequate contraception during their participation</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>